ZÜRICH, June 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing therapies for central ...

ZÜRICH, SWITZERLAND / ACCESS Newswire / March 31, 2025 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing ...

(RTTNews) - NLS Pharmaceutics AG (NLSP) and Kadimastem Ltd. (KDST.TA), which announced their plan to form a combined Nasdaq-listed biotechnology company last month, have today introduced a new ...

We are delighted to share a summary of NLS Pharmaceutics' achieved milestones since the fourth quarter of 2024. Here's a snapshot of our progress and what lies ahead: Since we first announced the ...

Last year, the Royal Pharmaceutical Society of Great Britain held a consultation regarding how the profession should develop during the next 12 years. An analysis of the results has just been ...

NLS Pharmaceutics (NASDAQ:NLSP) rose in premarket trading on Monday after the company reported a definitive merger agreement with Kadimastem. NLSP (NLSP) stock climbed +57.22% to $5.66 +2.06 premarket ...

Mark Egerton, PhD, chief executive officer of Quotient Sciences, shares insights on a new approach to accelerate drug development, which integrates formulation development, real-time adaptive GMP ...

Molecular Pharmaceutics is a peer-reviewed scientific journal, published since 2004 by the American Chemical Society. MP is currently indexed in: Chemical Abstracts Service (CAS), SCOPUS, EBSCOhost, ...